|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||31.16 / 55.16|
Hospital companies are likely be hit the worst in the public markets given their dependency on policies under the Affordable Care Act.
Amedisys to Host Conference Call November 4, 2016 at 11:00 a.m. ET
The most recent short interest data has been released for the 09/15/2016 settlement date, which shows a 1,675,431 share increase in total short interest for Amedisys, Inc. , to 2,803,524, an increase of 148.52% since 08/31/2016.
Food and health care companies were among the top stocks chosen in the quarter by the top PE firms.
Both firms snapped up a wide variety of stocks in the second quarter, according to their filings to the SEC.
It's apparently not all doom and gloom in the private-equity realm of stock picking these days.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AMED, CGNX, CHGG, ENSG, FOMX, GATX, MIC, RPAI, SBRA, TDC, TSRI, TX, TZOO, WNRL Downgrades: AMIC, FE, SHPG, SOHU, TCBI Initiations: GPP Read on to get TheStreet Quant Ratings' detailed report:
Here's a technical look at several stocks that were rising on unusual volume recently.
Deepens Strategic Commitment to Personal Care, Extends Care for Patients in the Home
S&P 500 hits all-time high as Nasdaq 100 and Russell 2000 reach respectable levels.
Jefferies analyst Brian Tanquilut lists six stocks as his top picks on the heels of last week's Jefferies Healthcare Conference.
Amedisys to Host Conference Call May 4, 2016 at 11:00 A.M. ET
Program Exceeds NOMS National Average by 12.3%
Trade-Ideas LLC identified Amedisys (AMED) as a strong on high relative volume candidate